Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a602007
Pregnancy cat.  ?
Legal status  ?
ATC code B01AB09
Chemical data
Formula  ?
 N(what is this?)  (verify)

Danaparoid sodium (Orgaran) is an anticoagulant[1] that works by inhibiting activated factor X (factor Xa).

Danaparoid is considered a "low molecular weight heparin" by some sources, but is chemically distinct from heparin and thus has little cross-reactivity in heparin-intolerant patients.

It consists of a mixture of heparan sulfate, dermatan sulfate and chondroitin sulfate.[2]

It has also been described as a heparinoid.[3]



It is used to prevent deep venous clots, particularly in situations with a high risk of clot formation, such as after hip surgery.

It is also used as a heparinoid substitute in heparin-induced thrombocytopenia[4][5] (HIT) which may otherwise cause paradoxical thrombosis. Danaparoid is used for thrombosis prophylaxis and treatment in heparin-induced thrombocytopenia patients, although cross-reactivity with heparin-induced antibodies can occur in 10–20% of the patients (ESRA). It has been proposed for use in Kasabach-Merritt syndrome.[6]


On August 14, 2002, this drug was withdrawn by Organon International.[7] Due to a shortage in drug substance, the manufacturer discontinued providing the medication in the United States. It is available in several other countries.[8]

On the Schering-Plough website, Orgaran is described as "Marketed outside the U.S."[9]


IV and SC

Side effects

  • Bleeding problems
  • Low platelets, due to a low level of structural similarity between danaparoid and heparin
  • Asthma exacerbations, due to allergies to sulfites contained within the medicine


  1. ^ Hagiwara S, Iwasaka H, Hidaka S, Hishiyama S, Noguchi T (2008). "Danaparoid sodium inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats". Crit Care 12 (2): R43. doi:10.1186/cc6851. PMC 2447588. PMID 18380908. http://ccforum.com/content/12/2/R43. 
  2. ^ de Pont AC, Hofstra JJ, Pik DR, Meijers JC, Schultz MJ (2007). "Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study". Crit Care 11 (5): R102. doi:10.1186/cc6119. PMC 2556745. PMID 17854496. http://ccforum.com/content/11/5/R102. 
  3. ^ "Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators". JAMA 279 (16): 1265–72. 1998. doi:10.1001/jama.279.16.1265. PMID 9565006. http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=9565006. 
  4. ^ Schindewolf M, Magnani HN, Lindhoff-Last E (May 2007). "[Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases"] (in German). Hamostaseologie 27 (2): 89–97. PMID 17479171. http://www.schattauer.de/index.php?id=1268&pii=ha07020089&no_cache=1. 
  5. ^ Magnani HN, Gallus A (June 2006). "Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004". Thromb. Haemost. 95 (6): 967–81. doi:10.1160/TH05-07-0489. PMID 16732376. http://www.schattauer.de/index.php?id=1268&pii=th06060967&no_cache=1. 
  6. ^ Ontachi Y, Asakura H, Omote M, Yoshida T, Matsui O, Nakao S (November 2005). "Kasabach-Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid". Haematologica 90 Suppl: ECR29. PMID 16266920. http://www.haematologica.org/cgi/pmidlookup?view=long&pmid=16266920. 
  7. ^ "Danaparoid (Subcutaneous Route) - MayoClinic.com". http://www.mayoclinic.com/health/drug-information/DR600517. Retrieved 2007-08-23. 
  8. ^ "Heparin Induced Thrombocytopenia" Uptodate www.uptodate.com retrieved on 2/6/2009
  9. ^ "Schering-Plough - Products and Care - A-Z Product Listing". http://www.schering-plough.com/schering_plough/pc/product_list2.jsp. Retrieved 2008-08-23. 

External links